EMA explains how to present biopharmaceutical, bioanalytical data in CTD format
This article was originally published in SRA
The European Medicines Agency has issued final guidance on how generic drug manufacturers should present biopharmaceutical and bioanalytical data when submitting applications in the common technical document (CTD) format1.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.